No Data
No Data
Express News | Merus NV : Jefferies Raises Target Price to $77 From $57
Merus Presented Interim Data On MCLA-145 Monotherapy And In Combination With Pembrolizumab At ASCO 2024
Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics and Triclonics), today announced upd
Express News | Merus NV : Leerink Partners Raises Target Price to $88 From $65
Express News | Merus NV Shares up 2.8% Premarket After Announcing Pricing of Upsized Public Offering of Common Shares
Merus Prices $400.2 Million Public Share Offering
Merus (MRUS) said late Wednesday it priced a public offering of about 7.6 million common shares at $53 per share. The gross proceeds from the offering are expected to total about $400.2 million. The o
Merus: Offering Is Expected to Close on or About May 31, 2024 >MRUS
Merus: Offering Is Expected to Close on or About May 31, 2024 >MRUS